This site is intended for managed care professionals in the U.S.

This site is intended for managed care professionals in the U.S.

Professionals in Canada should visit

Continuous Glucose Monitoring

Education for Managed Care, Pharmacy, and Payer Professionals

Faculty Advisor Daniel DeSalvo, MD

Daniel DeSalvo, MD
Director of Strategic Collaboration, Texas Children’s Diabetes & Endocrine Care Center, Texas Children’s Hospital
Type 1 Diabetes Clinic Lead, Texas Children’s Hospital
Diabetes Transition Clinic Co-Lead, Texas Children’s Hospital
Assistant Professor, Baylor College of Medicine

Daniel DeSalvo joined the Texas Children’s Hospital Section of Pediatric Diabetes and Endocrinology in July 2015 after completing a postdoctoral fellowship at Stanford University. He serves as the Type 1 Diabetes Clinic Lead, Director of Strategic Collaboration for the Texas Children’s Diabetes & Endocrine Care Center, and TCH Diabetes Transition Clinic Co-Lead. His overarching career goal as a pediatric endocrinologist is to provide compassionate and comprehensive care to youth with diabetes, and to advance clinical care through patient-centered research and quality improvement endeavors. His clinical and research focus is on emerging diabetes technology and therapies (including continuous glucose monitoring and closed-loop automated insulin delivery systems) for improving clinical outcomes and reducing the burden of care. It was through his personal experience living with type 1 diabetes, and a desire to help others on a similar journey that motivated him to become a pediatric endocrinologist.

Perspective on Real-Time CGM:

“CGM has become the standard of care for diabetes management. At our site, Texas Children’s Hospital, which is a very heterogeneous population in Houston, our cross-sectional analysis showed that patients using CGM had a lower A1C than patients not using CGM, and that was true for both pump and injection users. As such, we have had a quality improvement project to try to improve the rates of CGM use. At this point, we now have over 70% of patients starting on CGM within 3 months of diagnosis. Additionally, Texas Medicaid is now covering CGM.”

Learn more from Dr. DeSalvo about the clinical and economic consequences of imprecise glycemic control in a new era of telehealth management in the CE activity: Presents: The Value of Continuous Glucose Monitoring during the COVID-19 Pandemic and New Era of Digital Healthcare



PHP Code Snippets Powered By :